eupraxia pharmaceuticals reports erefs data from its ongoing phase 1b2a resolve trial in eosinophilic esophagitis at digestive disease week ddw

EPU_CATS_REGULATIONEPU_CATS_FINANCIAL_REGULATIONMANMADE_DISASTER_IMPLIEDWB_2299_PIPELINES

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.